Patents by Inventor Paul Charifson

Paul Charifson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250214970
    Abstract: The present disclosure is directed to compounds of formula (I): wherein R1, R2, R3, R3a, R4, Y, and X are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.
    Type: Application
    Filed: November 5, 2024
    Publication date: July 3, 2025
    Inventors: Verner Alexander LOFSTRAND, Jung Yun KIM, Helen CLEMENT, Kristen Nicole BURFORD, Paul CHARIFSON, Shawn JOHNSTONE, Juliette SABBATANI, Jan Felix SCHOLTES, Wei ZHANG, Shaoyi SUN, Michael CLARK, Steve WESOLOWSKI, Ravi MUNUGANTI, Ramkumar RAJAMANI
  • Publication number: 20250129044
    Abstract: The present disclosure is directed to compounds of formula (I): wherein X, Y, Z, R1, R2a, R2b, R3, and L are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.
    Type: Application
    Filed: May 21, 2024
    Publication date: April 24, 2025
    Inventors: Verner Alexander LOFSTRAND, Jung Yun KIM, Helen CLEMENT, Kristen Nicole BURFORD, Paul CHARIFSON, Michael CLARK
  • Publication number: 20250059214
    Abstract: Disclosed are compounds according to Formula (1) which inhibit LONP1, and pharmaceutical compositions comprising compounds of the disclosure. Compounds and pharmaceutical compositions of the disclosure may be useful for the treatment of diseases and disorders associated with LONP1, including oncologic diseases and disorders, such as cancer, and diseases and disorders related to mitochondrial dysfunction, such as neurodegenerative disorders, metabolic disorders, and diseases associated with the aging process. The disclosure also relates to methods of using such compounds and compositions for the treatment of such diseases and disorders.
    Type: Application
    Filed: December 6, 2022
    Publication date: February 20, 2025
    Applicant: Pretzel Therapeutics, Inc.
    Inventors: Jeremy Green, Paul Charifson, Gabriel Martinez Botella, Andrew Griffin
  • Publication number: 20250059189
    Abstract: The present disclosure is directed to compounds of formula (I): wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.
    Type: Application
    Filed: June 18, 2024
    Publication date: February 20, 2025
    Inventors: Verner Alexander LOFSTRAND, Jung Yun KIM, Helen CLEMENT, Kristen Nicole BURFORD, Paul CHARIFSON, Shawn JOHNSTONE, Juliette SABBATANI, Jan Felix SCHOLTES, Wei ZHANG, Shaoyi SUN
  • Publication number: 20250059213
    Abstract: Disclosed are compounds according to Formula (1) and Formula (2) which inhibit LONP1, and pharmaceutical compositions comprising compounds of the disclosure. Compounds and pharmaceutical compositions of the disclosure may be useful for the treatment of diseases and disorders associated with LONP1, including oncologic diseases and disorders, such as cancer, and diseases and disorders related to mitochondrial dysfunction, such as neurodegenerative disorders, metabolic disorders, and diseases associated with the aging process. The disclosure also relates to methods of using such compounds and compositions for the treatment of such diseases and disorders.
    Type: Application
    Filed: December 6, 2022
    Publication date: February 20, 2025
    Applicant: Pretzel Therapeutics, Inc.
    Inventors: Jeremy Green, Paul Charifson, Gabriel Martinez Botella, Andrew Griffin
  • Publication number: 20250051367
    Abstract: Disclosed are compounds according to Formula (1) which inhibit LONP1, and pharmaceutical compositions comprising compounds of the disclosure. Compounds and pharmaceutical compositions of the disclosure may be useful for the treatment of diseases and disorders associated with LONP1, including oncologic diseases and disorders, such as cancer, and diseases and disorders related to mitochondrial dysfunction, such as neurodegenerative disorders, metabolic disorders, and diseases associated with the aging process. The disclosure also relates to methods of using such compounds and compositions for the treatment of such diseases and disorders.
    Type: Application
    Filed: December 6, 2022
    Publication date: February 13, 2025
    Applicant: Pretzel Therapeutics, Inc.
    Inventors: Jeremy Green, Paul Charifson
  • Patent number: 12054486
    Abstract: The present disclosure is directed to compounds of formula (1): wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.
    Type: Grant
    Filed: September 23, 2022
    Date of Patent: August 6, 2024
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Verner Alexander Lofstrand, Jung Yun Kim, Helen Clement, Kristen Nicole Burford, Paul Charifson, Shawn Johnstone, Juliette Sabbatani, Jan Felix Scholtes, Wei Zhang, Shaoyi Sun
  • Publication number: 20230203007
    Abstract: The present disclosure is directed to compounds of formula (I): wherein R1, R2, R3, R3a, R4, Y, and X are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.
    Type: Application
    Filed: September 23, 2022
    Publication date: June 29, 2023
    Inventors: Verner Alexander Lofstrand, Jung Yun Kim, Helen Clement, Kristen Nicole Burford, Paul Charifson, Shawn Johnstone, Juliette Sabbatani, Jan Felix Scholtes, Wei Zhang, Shaoyi Sun, Michael Clark, Steve Wesolowski, Ravi Munuganti, Ramkumar Rajamani
  • Publication number: 20230150972
    Abstract: The present disclosure is directed to compounds of formula (I): wherein X, Y, Z, R1, R2a, R2b, R3, and L are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.
    Type: Application
    Filed: September 23, 2022
    Publication date: May 18, 2023
    Inventors: Verner Alexander Lofstrand, Jung Yun Kim, Helen Clement, Kristen Nicole Burford, Paul Charifson, Michael Clark
  • Publication number: 20230144095
    Abstract: The present disclosure is directed to compounds of formula (1): wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.
    Type: Application
    Filed: September 23, 2022
    Publication date: May 11, 2023
    Inventors: Verner Alexander Lofstrand, Jung Yun Kim, Helen Clement, Kristen Nicole Burford, Paul Charifson, Shawn Johnstone, Juliette Sabbatani, Jan Felix Scholtes, Wei Zhang, Shaoyi Sun
  • Patent number: 8426426
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: April 23, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Joseph Drumm, Anne-Laure Grillot, Yusheng Liao, Patricia Oliver-Shaffer, Dean Stamos
  • Patent number: 8394803
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: March 12, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Joseph Drumm, Anne-Laure Grillot, Arnaud LeTiran, Yusheng Liao, Emanuele Perola, Steven Ronkin, Dean Stamos, Tiansheng Wang
  • Publication number: 20130030004
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, that inhibit bacterial gyrase and/or TopoIV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Application
    Filed: November 6, 2006
    Publication date: January 31, 2013
    Inventors: Paul Charifson, David Deininger, Joseph Drumm, Anne-Laure Grillot, Arnaud LeTiran, Yusheng Liao, Emanuele Perola, Steven Ronkin, Dean Stamos, Tiansheng Wang
  • Patent number: 8202889
    Abstract: The present invention relates to methods of inhibiting bacterial IMPDH comprising administering compounds of formula I: or pharmaceutically acceptable salts thereof. The present invention also relates to pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infections.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: June 19, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, Trudy Grossman, Emanuele Perola
  • Patent number: 8193352
    Abstract: The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: June 5, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Anne-Laure Grillot, Yusheng Liao, Steven Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud LeTiran, Joseph Drumm
  • Patent number: 8188095
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: May 29, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Anne-Laure Grillot, Yusheng Liao, Steven Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud Le Tiran, Joseph Drumm
  • Publication number: 20120010222
    Abstract: The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.
    Type: Application
    Filed: September 16, 2011
    Publication date: January 12, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Paul Charifson, David Deininger, Anne-Laure Grillot, Yusheng Liao, Steven Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud Le Tiran, Joseph Drumm
  • Patent number: 8067606
    Abstract: The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: November 29, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Anne-Laure Grillot, Yusheng Liao, Steven Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud LeTiran, Joseph Drumm
  • Patent number: 8034832
    Abstract: The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: October 11, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Anne-Laure Grillot, Yusheng Liao, Steven Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud LeTiran, Joseph Drumm
  • Publication number: 20110104207
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.
    Type: Application
    Filed: April 16, 2010
    Publication date: May 5, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Paul CHARIFSON, David DEININGER, Joseph DRUMM, Anne-Laure GRILLOT, Yusheng LIAO, Patricia OLIVER-SHAFFER, Dean STAMOS